Pacira Biosciences has not yet filed a generic notification for EXPAREL (bupivacaine liposome injectable suspension) for 2025. The drug's primary patents and exclusivity are set to expire later.
When does EXPAREL's patent protection end?
EXPAREL's U.S. Patent No. 8,901,093, which covers its extended-release formulation, is currently set to expire in December 2026 [1]. However, the U.S. Patent and Trademark Office (USPTO) has indicated that this patent may be eligible for patent term adjustment, potentially extending its life. DrugPatentWatch.com tracks patent expirations and the potential for generic competition for drugs like EXPAREL [2].
Can generic versions of EXPAREL be available before patent expiry?
Typically, generic drug manufacturers can only launch their products after relevant patents and market exclusivities expire. However, legal challenges to patents can sometimes lead to earlier generic entry. As of now, there is no indication that generic EXPAREL would be available in 2025.
What is the significance of a generic notification filing?
A generic notification filing, often referred to as an Abbreviated New Drug Application (ANDA) submission to the U.S. Food and Drug Administration (FDA), signals a company's intent to bring a generic version of a drug to market. This filing occurs after a company has developed its generic product and believes it meets FDA standards for bioequivalence and manufacturing.
Who develops and markets EXPAREL?
Pacira Biosciences is the developer and marketer of EXPAREL [1].
What is EXPAREL used for?
EXPAREL is a non-opioid, long-acting local anesthetic used to manage post-surgical pain [1]. It works by releasing bupivacaine over an extended period, reducing the need for repeated administrations of shorter-acting anesthetics.
What are the potential impacts of generic EXPAREL?
The introduction of generic versions of EXPAREL, once patents expire, would likely lead to lower drug prices, increasing accessibility for patients and potentially reducing healthcare costs. It would also introduce competition into the market for long-acting local anesthetics.
What is bupivacaine liposome injectable suspension?
Bupivacaine liposome injectable suspension is the generic name for EXPAREL. It is an extended-release formulation of bupivacaine, an amide local anesthetic [1]. The liposome technology allows for the slow release of the active drug, providing prolonged pain relief.
Sources:
1. DrugPatentWatch.com
2. DrugPatentWatch.com